Bispecific Antibody Simultaneously Targeting PD1 and HER2 Inhibits Tumor Growth via Direct Tumor Cell Killing in Combination with PD1/PDL1 Blockade and HER2 Inhibition

Scientists developed a bispecific antibody simultaneously targeting both PD1 and HER2 in an attempt to combine HER2-targeted therapy with immune checkpoint blockade for treating HER2-positive solid tumors.